Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial

BACKGROUND: COVID-19 morbidity and mortality remains high and the need for safe and effective drugs continues despite vaccines. METHODS: Double-blind, placebo-controlled, multi-centre, randomised, parallel group phase 2 trial to evaluate safety and efficacy of oral angiotensin II type 2 receptor ago...

Descripción completa

Detalles Bibliográficos
Autores principales: Tornling, Göran, Batta, Rohit, Porter, Joanna C., Williams, Bryan, Bengtsson, Thomas, Parmar, Kartikeya, Kashiva, Reema, Hallberg, Anders, Cohrt, Anne Katrine, Westergaard, Kate, Dalsgaard, Carl-Johan, Raud, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542174/
https://www.ncbi.nlm.nih.gov/pubmed/34723163
http://dx.doi.org/10.1016/j.eclinm.2021.101152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542174/
https://www.ncbi.nlm.nih.gov/pubmed/34723163
http://dx.doi.org/10.1016/j.eclinm.2021.101152

Ejemplares similares